Drug Trial Radar · NCT04265651
Study of Infigratinib in Children With Achondroplasia
Last checked: Nov 20, 2026Latest source record: Oct 22, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
84
Actual
Start
Mar 10, 2020
Primary completion
Oct 21, 2024
Study completion Oct 21, 2024
Sponsor
- Lead sponsor
- QED Therapeutics, a BridgeBio companyIndustry
- Sponsor type
- Industry
- First posted
- Feb 11, 2020
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 3 years, up to 11 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 2, multicenter, open-label, dose-escalation and dose-expansion study to evaluate the safety, tolerability, and efficacy of infigratinib, a fibroblast growth factor receptor (FGFR) 1-3-selective tyrosine kinase inhibitor, in children 3 to 11 years of age with Achondroplasia (ACH) who previously participated in the PROPEL study (Protocol QBGJ398-001) for at least 6 months. The study includes dose escalation with extended treatment, and dose expansion. The study also includes a PK Substudy to fully characterize the pharmacokinetics of infigratinib in children with ACH.
Conditions
- Achondroplasia
Interventions
Infigratinib 0.016 mg/kgDrug
Initial cohort dose of infigratinib at the protocol-specified starting dose, with subsequent cohort escalations based on protocol-specific criteria. Infigratinib tablets to be administered by mouth.
Infigratinib 0.032 mg/kgDrug
Subsequent cohort dose escalation based on protocol-specific criteria. Infigratinib tablets to be administered by mouth.
Infigratinib 0.064 mg/kgDrug
Subsequent cohort dose escalation based on protocol-specific criteria. Infigratinib tablets to be administered by mouth.
Infigratinib 0.128 mg/kgDrug
Subsequent cohort dose escalation based on protocol-specific criteria. Infigratinib tablets to be administered by mouth.
Infigratinib 0.25 mg/kgDrug
Subsequent cohort dose escalation based on protocol-specific criteria. Infigratinib tablets to be administered by mouth.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of treatment-emergent adverse events (TEAEs) that lead to dose decrease or discontinuationTime frame: Up to 18 months
- Change from baseline in annualized height velocityTime frame: Up to 18 months
- PK parameters of infigratinib (Cmax- PK substudy only)Time frame: 21 days
- PK parameters of infigratinib (Clast- PK substudy only)Time frame: 21 days
- PK parameters of infigratinib (Tmax- PK substudy only)Time frame: 21 days
- PK parameters of infigratinib (AUC24- PK substudy only)Time frame: 21 days
- PK parameters of infigratinib (T1/2- PK substudy only)Time frame: 21 days
- PK parameters of infigratinib (AUCinf- PK substudy only)Time frame: 21 days
- PK parameters of infigratinib (CL/F- PK substudy only)Time frame: 21 days
- PK parameters of infigratinib (Vz/F- PK substudy only)Time frame: 21 days
- PK parameters of infigratinib (Racc- PK substudy only)Time frame: 21 days
Locations
19 sites in 6 countries. Site status is shown where the registry gives one.
UCSF Benioff Children's Hospital
Oakland, California
Nemours Alfred I. Dupont Hospital for Children
Wilmington, Delaware
Johns Hopkins School of Medicine
Baltimore, Maryland
Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio
Vanderbilt University Medical Center
Nashville, Tennessee
Murdoch Children's Hospital
Parkville, Victoria, Australia
Stollery Children's Hospital
Edmonton, Alberta, Canada
Hopital Femme Mere Enfant
Lyon, France
Hopital Necker-Enfants Malades
Paris, France
Hopital des Enfants
Toulouse, France
Hospital Universitario La Paz
Madrid, Spain
Hospital Universitario Virgen de la Victoria
Málaga, Spain
Vithas Hospital San José
Vitoria-Gasteiz, Álava, Spain
Birmingham Children's Hospital
Birmingham, United Kingdom
University Hospitals Bristol and Weston NHS Foundation Trust
Bristol, United Kingdom
Queen Elizabeth University Hospital
Glasgow, United Kingdom
Evelina London Children's Hospital
London, United Kingdom
Manchester University Children's Hospital
Manchester, United Kingdom
Sheffield Children's Hospital
Sheffield, England, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.